Patent ID: 7928246

Claim:
A pharmaceutical composition of wherein R 1 is H or C 1-6 alkyl optionally substituted with optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl; R 2 is 0-3 members independently selected from halo and optionally substituted C 1-6 alkyl, A is aryl; B is heteroaryl said heteroaryl being connected to N(1) through a ring carbon atom adjacent to a ring nitrogen, and additionally said heteroaryl having an additional 0 to 3 heteroatoms selected from 0, S, and N, wherein one or more ring nitrogen atoms in said heteroaryl can be optionally in an N-oxide form, and said heteroaryl being further optionally substituted with 1 or 2 members selected from optionally substituted C 1-4 alkyl, optionally substituted C 2-4 alkenyl, halo, —CN, aryl, heteroaryl, heterocyclyl, —SO 3 H, —C(O)OH, —C(O)O—C 1-4 alkyl, —OR 4 , —C(O)R 4 , —N(R 4 )(R 5 ), —C(O)—N(R 4 )(R 5 ), —S(O) 2 —R 4 , and —S(O) 2 —N(R 4 )(R 5 ), wherein R 4 and R 5 are independently selected from H, C 1-6 alkyl, aryl, heteroaryl, and heterocyclyl; X is optionally substituted C 1-3 alkylene; and Y is O, S, S(O), S(O) 2 , or N(H); or an optical isomer, enantiomer, diastereomer, racemate, or pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, further comprising at least one additional agent, drug, medicament, antibody and/or inhibitor for treating, ameliorating or preventing a glucokinase mediated disease.